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A
 
BSTRACT
Background:
 
To determine the effects of 1 months
treatment with optimized high-dose inhaled cortico-
steroid on surrogate markers of airways inflammation,
as well as lung function, in a clinical setting.
 
Methods:
 
Nine steroid-treated asthmatics (mean
dose 778 
 
µ
 
g/day) with uncontrolled disease were all
switched to 1 months treatment with 2000 
 
µ
 
g/day
inhaled beclomethasone dipropionate dry powder.
Serial spot clinic measurements were made of pre- and
post-treatment effects on sputum eosinophils, serum
eosinophil cationic protein (ECP), bronchial hyper-
responsiveness (BHR) to methacholine, exhaled nitric
oxide (NO), spirometry and domiciliary peak expiratory
flow rate (PEF), symptom score and reliever use.
 
Results:
 
Optimization of inhaled corticosteroid treat-
ment had further significant (
 
P
 
 < 0.05) beneficial
effects only on sputum eosinophils, BHR, symptom
score and morning PEF. Furthermore, treatment
decreased the eosinophil count in all cases.
 
Conclusions:
 
Serial clinic measurements of sputum
eosinophils and BHR may provide additional informa-
tion on asthmatic inflammation to assess the response
to inhaled steroids in patients who have uncontrolled
asthma.
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I
 
NTRODUCTION
 
Asthma is defined by the triad of reversible airflow
obstruction, airway inflammation and bronchial hyper-
responsiveness (BHR). Current asthma management
guidelines state that, for patients with uncontrolled
disease, their therapy should be initially optimized with
high-dose inhaled corticosteroids.
 
1
 
 How we best monitor
treatment responses that reflect the different aspects of
the asthma phenotype has been the subject of some
debate.
Airflow obstruction is traditionally monitored by home
peak expiratory flow (PEF) recordings, as well as spot
spirometry checks in the clinic, and BHR is monitored
by bronchial challenge with histamine or methacholine.
However, there is still much debate concerning the best
method for monitoring airway inflammation in these
patients. The gold standard is fiberoptic bronchoscopy
with biopsy and bronchoalveolar lavage, but this is both
inappropriate and impractical in day-to-day clinical prac-
tice. Several other less-invasive measurements are avail-
able, including exhaled tidal nitric oxide (NO) and
sputum or serum eosinophils and eosinophil cationic
protein (ECP). In addition, BHR is an indirect measure of
inflammation, but also probably reflects other aspects of
airway changes in asthma, in particular airway remodel-
ing.
 
2
 
 While the use of these inflammatory markers is
relatively common in research,
 
3,4
 
 it is still rare when
monitoring treatment in clinical practice, even though
their utilization has been shown to help predict exacer-
bations and reduce airway remodeling.
 
5,6
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Therefore, the aim of the present study was to
compare changes in various surrogate markers of
airway inflammation, as well as more commonly used
markers of asthma control, during optimization of inhaled
corticosteroid treatment for patients with uncontrolled
disease.
 
M
 
ETHODS
 
Steroid-treated patients with moderate to severe persist-
ent asthma who were uncontrolled (i.e. daily reliever use
and symptoms) attending the asthma clinic had spir-
ometry and bronchial challenge with methacholine
performed. To be eligible for the trial, the patients had
to have a forced expiratory volume in 1 s (FEV
 
1
 
) greater
than 50% predicted, methacholine PD
 
20
 
 less than
200 
 
µ
 
g and not have been treated with systemic corti-
costeroids (oral, intravenous or intramuscular) in the
previous 3 months. Blood was taken for estimation of
serum ECP, exhaled tidal NO was measured and
induced sputum performed for eosinophil count. Patients
were then treated with 2000 
 
µ
 
g/day inhaled beclo-
methasone dipropionate (BDP) dry powder inhaler (as
the Asmabec 250 Clickhaler; four puffs, b.i.d.; Medeva
Pharma, Leatherhead, UK) for 4 weeks. This is a high-
efficiency breath-actuated inhaler and has a counter
to facilitate checking of compliance. During this time,
patients kept home recordings of morning and evening
PEF, symptom scores (on a scale of 0–3) and reliever
use, and then returned to the clinic to have repeat
measurements taken. Written informed consent was
obtained from each patient prior to entering the treat-
ment period and the protocol was approved by the
Tayside Committee on Medical Research Ethics.
 
Measurements
 
Exhaled breath NO was measured according to recom-
mended guidelines using an integrated LR2000 clinical
real-time NO gas analyzer with an accuracy of 2 p.p.b.
NO with a response time of 2 s (Logan Research,
Rochester, UK).
 
7
 
 Using this method, the normal rage for
non-asthmatics is an exhaled breath NO less than
6 p.p.b. Spirometry was performed using a Vitalograph
Compact spirometer (Vitalograph, Buckingham, UK),
calibrated daily, according to current American Thoracic
Society guidelines.
 
8
 
 Bronchial challenge with metha-
choline was performed using the validated dosimetric
method described previously by Beach 
 
et al.
 
9
 
Following methacholine challenge, patients inhaled
400 
 
µ
 
g salbutamol, then, after 15 min, had spirometry
checked to make sure their FEV
 
1
 
 had returned to within
5% of baseline. A safety cut-off was calculated as 80% of
post-salbutamol FEV
 
1
 
. Patients then inhaled hypertonic
saline from an ultrasonic nebuliser (Medix Sonix 2000;
Clement Clarke, Essex, UK) in increasing strengths (3, 4
and then 5%) and had sputum induced and analyzed as
described by Pin 
 
et al.
 
10
 
 Sputum induction was stopped
early if the patient’s FEV
 
1
 
 fell below the safety cut-off or
when a satisfactory sample was obtained. Sputum
samples were stored on ice and processed within 30 min.
Cytospin preparations of dithiothreitol-treated sputum
samples were stained using a modified Giemsa stain.
Cell counts were performed in a blinded fashion using
a 
 
× 
 
40 objective. A minimum of 500 nucleated non-
squamous cells was counted in order to quantify the
percentage of eosinophils present. Only those cells
touching horizontal lines of a graticule grid were
counted. This was done in order to avoid bias in the cell
counts. Slides containing > 20% squamous cells were
regarded as representing salivary contamination and
were excluded. After a preliminary trial period in order to
ensure reproducible data, study samples were counted,
each slide being counted twice in order to minimize intra-
observer variability. Serum ECP was measured in dupli-
cate using a radioimmunoassay (RIA) kit (Pharmacia and
Upjohn Diagnostics, Upsala, Sweden). The within-assay
coefficient of variation for the RIA kit was 4.7%.
 
Statistical analysis
 
Data for exhaled NO, methacholine PD
 
20
 
, sputum
percentage eosinophils and serum ECP were log trans-
formed to normalize their distribution prior to analysis.
Mean data for morning and evening symptom scores
and reliever use were combined to give total daily values
for each. Data at baseline and post-treatment with
2000 
 
µ
 
g BDP were compared using one-way analysis of
variance, with the alpha error set at 0.05 (two-tailed).
 
R
 
ESULTS
 
Nine patients (seven males) completed the study. The
mean (
 
±
 
 SEM) patient age was 50 
 
±
 
 3 years, the mean
inhaled corticosteroid dose was 778 
 
±
 
 190 
 
µ
 
g (one
budesonide, two fluticasone and six beclomethasone),
the mean FEV
 
1
 
 was 67 
 
±
 
 4% predicted, reversibility to
inhaled salbutamol 400 
 
µ
 
g was 16 
 
±
 
 2% for FEV
 
1
 
 and
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23 
 
±
 
 4% for the forced midexpiratory flow rate (FEF
 
25–75
 
)
and the mean methacholine PD
 
20
 
 was 36 
 
±
 
 14 
 
µ
 
g.
Mean compliance was 93 
 
±
 
 3% of prescribed doses
taken over the 1 month period.
Results are shown in Table 1. Over the 4 week period,
sputum eosinophils decreased by geometric mean nine-
fold, methacholine PD
 
20
 
 increased by 1.4 doubling
doses, morning PEF increased by 24 L/min and daily
symptom score (on a scale of 0–6) fell from 1.6 to 0.7.
No significant improvements occurred in exhaled NO,
serum ECP, FEV
 
1
 
, FEF
 
25–75
 
, evening PEF or daily reliever
use.
Individual data are shown in Fig. 1. Every patient had
a decrease in the eosinophil count and six patients
had an increase in the methacholine PD
 
20
 
 of at least
twofold, whereas four patients had an improvement in
morning PEF of at least 20 L/min.
 
D
 
ISCUSSION
 
The present study has examined the changes that occur
in a wide range of asthma markers following optimiza-
tion of inhaled corticosteroid dose over 4 weeks in
patients with uncontrolled moderate to severe asthma.
There were significant improvements in sputum eosin-
ophil counts, BHR, morning PEF and symptom scores,
but not in exhaled NO, serum ECP, spirometry or
reliever use. Furthermore, our patients were not selected
 
Table 1
 
Data at baseline (on mean 778 
 
µ
 
g/day inhaled corticosteroids) and after 4 weeks treatment with 2000 
 
µ
 
g/day inhaled
beclomethasone dipropionate
Baseline Post 2000 
 
µ
 
g BDP Difference (95% CI)
Inflammatory markers
Sputum eosinophils (%) 4.1 
 
± 
 
1.9 0.5 
 
± 
 
0.2* 9.0 (3.5, 22.8)
Methacholine PD
 
20
 
 (
 
µ
 
g) 36.2 
 
± 
 
13.8 97.9 
 
± 
 
45.4* 2.7 (1.5, 4.8)
Exhaled NO (p.p.b.) 6.94 
 
± 
 
1.85 6.03 
 
± 
 
1.31 1.1 (0.7, 1.8)
Serum ECP (
 
µ
 
g/L) 18.08 
 
± 
 
4.44 13.56 
 
± 
 
3.11 1.4 (0.8, 2.4)
Spirometry
FEV
 
1
 
 (% predicted) 66.9 
 
± 
 
3.5 68.4 
 
± 
 
2.9 1.6 (–4.8, 7.9)
FEF
 
25–75
 
 (% predicted) 38.6 
 
± 
 
5.1 39.7 
 
± 
 
4.4 1.1 (–6.2, 8.5)
Home diary data
Morning PEF (L/min) 430 
 
± 
 
25 454 
 
± 
 
26* 24 (8, 39)
Evening PEF (L/min) 436 
 
± 
 
27 444 
 
± 
 
29 7 (–11, 25)
Symptom score (0–6) 1.56 
 
± 
 
0.16 0.73 
 
± 
 
0.27* 0.82 (0.19, 1.47)
Reliever use (puffs/day) 1.98 
 
± 
 
0.55 1.24 
 
± 
 
0.42 0.73 (–1.04, 2.51)
 
Data are the geometric mean 
 
± 
 
SEM for inflammatory markers and arithmetic mean 
 
± 
 
SEM for bronchodilator markers. Fold differences are
shown for inflammatory markers and absolute differences are shown for bronchodilator markers. *
 
P
 
 < 0.05 compared with baseline.
NO, nitric oxide; ECP, Eosinophil cationic protein; FEV
 
1
 
, forced expiratory volume in 1 s; FEF
 
25–75
 
, forced midexpiratory flow rate; PEF, peak
expiratory flow rate; CI, confidence interval.
 
Fig. 1
 
Individual data for end-points shown, with significant
differences shown from 
 
ANOVA
 
. Each symbol identifies a given
patient. NO, nitric oxide; FEV
 
1
 
, forced expiratory volume in 1 s.
 74 SJ FOWLER 
 
ET AL.
for baseline sputum eosinophilia and, indeed, five had a
baseline eosinophilia of less than 3%. Hence, monitor-
ing of this marker may be of more widespread benefit
than previously thought. Induced sputum is a rarely used
tool in monitoring asthma control, although previous
data have shown it to be a safe and effective way to
monitor airway inflammation directly.
 
10,11
 
 Induced
sputum eosinophil counts may also be used to help
predict exacerbations during step-down of inhaled corti-
costeroids.
 
5
 
 Sputum eosinophil counts correlate well with
those in broncoalveolar lavage and bronchial biopsy,
 
12
 
but not with serum eosinophils and ECP.
 
13
 
The results of the present study reinforce previous data
that measurements of exhaled NO are not useful in
monitoring disease changes in people already treated
with inhaled corticosteroids
 
14
 
 and are suppressed to
levels seen in healthy non-asthmatics following treatment
with doses as low as 400 
 
µ
 
g/day inhaled budesonide.
 
4,15
 
Serum ECP is another surrogate inflammatory marker
with limited use in the real world. As mentioned above, it
does not reflect changes in airway inflammation and we
have shown, in a small group of suboptimally treated
patients, that it is not consistently affected even by high-
dose corticosteroid treatment.
We have demonstrated that BHR to methacholine
is significantly attenuated by treatment with high-dose
inhaled corticosteroids, even in patients already treated
with steroids. This is reassuring, because previous data
have suggested a shallow dose–response of metha-
choline to inhaled corticosteroids.
 
15,16
 
 Using BHR to
methacholine as a guide when tailoring asthma treat-
ment has been shown to reduce airway remodeling
 
6
 
 and
our data provide further evidence that this challenge may
be a useful tool when monitoring asthma control in the
out-patient clinic.
The lung function measures FEV
 
1
 
, FEF25–75 and PEF are
used traditionally as guides to treatment in the out-patient
setting. However, our data show that, except for morning
PEF, no mean improvement was seen when optimizing
the patients’ steroid dose, despite the fact that our
patients had bronchodilator reversibility. This is in line
with recent data from a meta-analysis showing that the
top of the dose–response for these markers occurs at a
dose of less than 500 µg fluticasone.17 Furthermore, the
dose–response for lung function parameters is known to
be much flatter than for ECP and BHR,15 hence the small
(24 L/min) but significant improvement in morning PEF.
It is worth pointing out that we used an efficient dry
powder inhaler to optimize lung delivery of inhaled
corticosteroid. For example, in one in vivo lung deposi-
tion study, the Clickhaler achieved better delivery of BDP
(31%) than a metered dose inhaled alone (9%) or with a
spacer (19%).18 This may explain why we were able to
achieve improvements in control compared with the
patients’ previously prescribed inhaled corticosteroid
therapy.
The present study illustrates one of the treatment
choices at step 3 of British Thoracic Society guidelines.19
We chose to use high doses of inhaled corticosteroids
rather than the alternative (i.e. medium-dose inhaled
corticosteroid plus second-line controller therapy, such
as inhaled long-acting β2-adrenergic receptor agonists).
However, adding a long-acting β2-adrenergic receptor
agonist to asthmatic patients’ existing treatment would
have had no impact on inflammatory markers, only on
smooth muscle tone, whereas we aimed to assess the
effect of optimizing anti-inflammatory therapy.
In conclusion, we have shown that sputum eosinophil
counts and bronchial challenge with methacholine can
provide useful extra information when used to assess the
response to optimizing the inhaled corticosteroid dose in
patients with uncontrolled asthma.
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